ATHERAPEUTIC attack on the immune system is initiated in anticipation of or in response to
immunologically mediated tissue damage. Drug regimens seek to inhibit selectively the T-…

Background Acute rejection episodes after renal transplantation are an important clinical
challenge, despite use of multidrug immunosuppressive regimens. We did a prospective, …

Background. Immunosuppressive drug therapy has been identified as one etiological factor
in the increased incidence of and deaths from malignancies in renal transplant recipients. In …

Background. A double-blind, placebo-controlled phase III study was performed to assess
whether basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, reduced the …

A series of human colonic epithelial cell lines have been cultured from a single patient: LS-180
the original adenocarcinoma, LS-174T a trypsinized variant, and normal colonic tissue. …

… Hodge(Cleveland Clinic Foundation, Cleveland, OH); Barry D. Kahan (University of Texas,
Houston, TX); Lawrence Kahana (Tampa General Hospital, Tampa, FL); Steven Steinberg (…

Background: Therapeutic drug monitoring (TDM) is essential to maintain the efficacy of many
immunosuppressant drugs while minimizing their toxicity. TDM has become more refined …

Sirolimus (previously known as rapamycin), a macrocyclic lactone, is a potent immunosuppressive
agent. Sirolimus was recently approved by the US Food and Drug Administration, on …

To assess the importance of cyclosporine pharmacokinetics on graft outcome and acute
rejection episodes, pretransplant and a total of 1868 posttransplant whole‐blood cyclosporine …

Sirolimus (Rapammune®, rapamycin, RAPA) is a potent immunosuppressive drug that reduces
renal transplant rejection. Hyperlipidemia is a significant side effect of sirolimus treatment…